Merrimack pushes back top line data for NAPOLI-1 to Q2 of 2014 Merrimack now expects to report top line data for NAPOLI-1, its Phase 3 clinical trial of MM-398 in advanced pancreatic cancer, in Q2 of 2014. Merrimack previously disclosed that top line data was expected in Q4 of 2013 or Q1 of 2014. This change is based on a blinded assessment of overall survival events across the entire trial, which are occurring later than forecasted. As previously disclosed, Merrimack met its enrollment target for the trial in August 2013.
News For MACK From The Last 14 Days
Check below for free stories on MACK the last two weeks.